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Abstract
Background: In left atrial appendage (LAA) closure, the correct sizing of the implantable 
devices is crucial. Data on the time-dependent changes in the shape and positioning of LAA 
occlusion devices are missing. We analyzed the results of 33 consecutive patients after implan-
tation of an Amplatzer™ Cardiac Plug (ACP) LAA closure device to get more information on 
the optimal device sizing during implantation. 
Methods and results: Thirty-three consecutive patients were enrolled in this observational 
study. ACP implantation was guided by fluoroscopy and three dimensional transesophageal 
echocardiography (3-D TEE). Device sizing was based on the largest measured diameter of 
the intended landing zone adding 2–4 mm of device oversizing. Fluoroscopies were performed 
at 1 day after, and after 3 months, control 3-D TEE was performed 3 months after implant-
ation. The stability of device positioning and shape was matched with the results of 3-D TEE. 
Patients’ mean age was 70.2 ± 8 years; mean CHA2DS2VASc score was 3.8 ± 1.1. According 
to the manufacture’s classification, the post-implant degree of compression of the device-lobe 
was classified in three categories 1) undercompression “square-like shape” (1 patient); 2) op-
timal compression “tire-like shape” (20 patients), 3) overcompression “strawberry-like shape”  
(12 patients). Changes in the degree of device compression by more than one classification class 
occurred in 18/33 of our patients. A complete loss of device compression (“square-like shape”) 
was observed in 9 patients. Despite the changes in device compression, a complete closure of 
the LAA was achieved in 32/33 patients.
Conclusions: There is a temporal change in shape and positioning of the ACP within  
3 months after implantation. A late decompression of the ACP lobe was observed in 61% of 
our patients, leading to a complete loss in device compression in 27%. This observation may 
be the rationale for a higher degree of ACP oversizing during implantation. (Cardiol J 2015; 
22, 2: 201–205)
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Introduction
Left atrial appendage (LAA) occlusion is an 
interventional “local” therapy for stroke pre-
vention in patients with atrial fibrillation [1–3]. 
A randomized clinical trial, together with a recently 
published long-term follow-up data, established 
LAA occlusion as non-inferior to warfarin therapy 
in the prevention of cardioembolic episodes in pa-
tients with atrial fibrillation [4, 5]. The current Eu-
ropean Society of Cardiology guidelines classified 
LAA occlusion as a class IIb therapy [6]. Assuming 
the great variability in LAA anatomy, the correct 
implantation and stable fixation of the devices may 
be technically challenging [7, 8]. Despite enor-
mous efforts in preimplantation diagnosis, using 
angiography, multiplane transesophageal echocar-
diography (TEE), 3-dimensional TEE, intracardiac 
echocardiography, computed tomography and mag-
netic resonance imaging, final device placement 
may not be always absolutely predictable [9–11]. 
The assurance of the temporal stability of the 
initially achieved shape and placement of the LAA 
closure device placement might be of importance 
for persisting complete LAA closure. In this manu-
script, our results on early and late post implant 
fluoroscopy to assess the temporal stability of the 
implanted Amplatzer™ Cardiac Plug (ACP) device 
were presented.
Methods
All patients undergoing percutaneous LAA clo-
sure with the ACP device between September 2011 
and January 2013 at our institution were enrolled 
in this prospective observation. The specifications 
of the implanted ACP device were published previ-
ously [3, 12]. The implantations were performed 
under heavy sedation and heparin therapy resulting 
in an activated clotting time > 300 s. The mean left 
atrial pressure was kept in a range > 12 mm Hg. 
The implantation was guided by angiography and 
3-D TEE in all patients. The device was oversized 
by 2–4 mm in relation to the largest echocardio-
graphic or angiographic diameter of the intended 
landing zone. Complete occlusion of the LAA was 
verified by color Doppler echocardiography prior 
to and immediately after release of the device. The 
resulting positioning of the device was verified by 
fluoroscopy in an optimized right anterior oblique 
(RAO) projection, which provides the best view 
on the relation of disc and lobe positioning of the 
implanted device. On day 1 after device implanta-
tion, the patients underwent a second fluoroscopy 
using the same optimized RAO projection. All 
patients received a dual antiplatelet therapy i.e. 
aspirin and clopidogrel for 3 months. All patients 
underwent repeat TEE and fluoroscopy 3 months 
later, as described above. All fluoroscopies obtained 
during implantation, after 1 day and after 12 weeks 
were analyzed, comparing disc-placement, lobe-
placement, lobe compression, and the distance 
between device disc and lobe over time. Examples 
of typical findings of position and shape of the ACP 
device are given in Figures 1 and 2.
The study was approved by the local ethical 
committee and all patients gave their written in-
formed consent.
Results
Thirty-five consecutive patients (20 female, 
15 male; mean age 70.2 ± 8.5 years) were enrolled 
in this observational study. ACP implantation was 
successful in 33 patients. In 1 patient, implanta-
tion was impossible due to an extremely small and 
angulated LAA, and 1 patient was excluded from 
the analysis due to device embolization. Seventeen 
patients showed permanent atrial fibrillation, while 
16 patients exhibited paroxysmal/persistent atrial 
fibrillation. The mean CHA2D2VASc score was 
3.8 ± 1.1. The majority of our patients had at 
least one contraindication to oral anticoagulation. 
The diameter of the implanted ACP devices was: 
18 mm (n = 2); 20 mm (n = 7); 22 mm (n = 3); 
24 mm (n = 7); 26 mm (n = 9); 28 mm (n = 4); 
30 mm (n = 1).
Regarding the classification of device-lobe 
compression, in 12 patients a “strawberry-like” 
overcompression of the ACP was achieved, in 
20 patients an optimal compression (“tire-like”), 
and in 1 patient an undercompression (“square-
like”), respectively [13]. A complete LAA-closure 
was achieved in all patients verified by 3-D TEE.
At fluoroscopy at day 1, 29 of 33 patients 
showed stable device placement compared to 
implantation. In 4 patients, an early change in 
device positioning was observed due to a too deep 
implantation of the ACP. Due to the tension of the 
“dish-like shaped“ device disc, deployment and 
minimal dislocation of the lobe of the device oc-
curred. In 1 patient with an early change in device 
positioning, an incomplete adaption of the disc in 
the area of the ridge to the left upper pulmonary 
vein could be detected by follow-up 3-D TEE (mi-
nor leak < 3 mm).
At 3-month follow-up fluoroscopy changes in 
the degree in compression of the device lobe — 
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more than one class — were observed in 18 of 
32 patients. These changes uniformly consist of an 
increase in the diameter and decompression of the 
lobe of the ACP. In 9 of the 12 patients with device 
overcompression, a change from a “strawberry-like 
shape” into a “tire-like shape” was observed. In 9 of 
the 20 patients with a “tire-like shape” a change into 
a “square-like shape” with a complete loss of device 
compression was observed (Fig. 1). An example of 
moderate decompression of the ACP lobe is given 
in Figure 2. No changes in device decompression, 
more than one class were observed in 14 patients. 
As a consequence of the decompression of the device 
lobe, a narrowing between lobe and the disc of the 
device occurred (Fig. 1). Despite these changes in late 
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Figure 2. This example of a 76-year-old male patient 
implanted with a 28 mm device shows the degree in de-
vice lobe decompression which occurred in the majority 
of our patients. The lobe compression during implanta-
tion could be classified as overcompressed (“strawber-
ry-like”) (A). During follow-up the decompression of 
the lobe leads to a lower degree in lobe compression 
(“tire-like“) (B).
Figure 1. This example of a 72-year-old male patient 
implanted with a 26 mm device demonstrates the nearly 
complete loss of the device lobe compression during 
follow-up. The degree of initial lobe compression during 
implantation is adequate (“tire-like“) (A). Lobe decom-
pression leads to narrowing of device lobe and disc 
(“square-like“) (B).
device position, there was not a single case of late 
occurrence of a peri-device leak. Device emboliza-
tion after successful implantation was not observed.
Discussion
The main finding of our observational study 
was that during follow-up, there was a variable 
degree in loss of device lobe compression in 
18/33 patients. In 9 of these patients, there was 
a complete loss of compression of the device lobe 
(from “tire-like shape” to “square-like shape”) 
[13]. However, despite the relevant changes in 
device compression, there was only 1 case of 
a peri-device leak. 
To the best of our knowledge, the presented 
study is the first report on the phenomenon of tem-
poral decompression of a LAA occluding device. 
During implantation the devices were oversized by 
2–4 mm in relation to the largest diameter of the 
intended “landing zone“. This approach in device 
selection is comparable to other studies on LAA 
occlusion using the ACP device [12, 13]. A specific 
amount of device oversizing is also used for implanta-
tion of the Watchman™ LAA occlusion device [1, 4]. 
There are no data linking device oversizing to 
specific procedure related complications, mainly 
pericardial effusions [13].
Incomplete LAA closures after implantation of 
a percutaneous closure device are reported for all 
devices [1–5, 13–15]. Sick and coworkers reported 
a 7% early peri-device flow in 75 Watchman™ 
patients [1]. In the PROTECT AF trial, Holmes 
et al. [4] reported a prolonged warfarin use due to 
a significant peri-device flow in 14% of their study 
patients at 45 days after implantation. In a more 
recent paper of the PROTECT AF investigators, 
a detailed analysis of this problem was presented. 
The investigators revealed a rate of any peri-device 
flow after Watchman™ implantation of 41% to 32%, 
after 1 month and 1 year; respectively [5]. Bai et 
al. [15] found an incidence of peri-device leaks in 
up to 35% in a series of 58 consecutive patients 
1 year after Watchman™ implantation. In this study, 
the leaks were more likely to become bigger and 
also new gaps occurred. In ACP implantation se-
ries, incomplete LAA closure was reported in the 
range of 4% to 21% of moderate to severe leaks 
[12, 13]. Despite the fact that we demonstrated rel-
evant changes in the compression of the implanted 
ACP devices a peri-device leak was found only in 
1 patient. In our study, we analyzed the shape of 
the implanted ACP 3 months after implantation. 
The observed device decompression might be 
a late phenomenon and may occur after fixing the 
device due to complete endothelialization of the 
device disc. However, earlier occurrence of device 
decompression, prior to complete endotheliazation, 
may lead to device dislocation and may cause peri-
device leaks. This may explain the observation by 
Freixa et al. [15] that a lower degree of ACP com-
pression was linked to the occurrence of late peri-
device leaks. In several implantation series with 
Plaato™, Watchman™ and Amplatzer™ devices, 
there was no association between the presence 
of residual peri-device flow and the occurrence 
of thromboembolic events [1, 2, 13, 14]. To our 
opinion, these results must be interpreted with 
caution due to the small sample size, low event 
rates and insufficient statistical power of these 
sub-analyses. Therefore, the benign character of 
residual peri-device leaks after percutaneous LAA 
occlusion is not proven and complete closure of the 
LAA should be attempted.
Conclusions
In the majority of our patients, there was 
a variable loss in device lobe compression of the 
implanted ACP. In connection with other presented 
clinical data we would like to support the strategy 
of a higher degree in device oversizing during ACP 
implantation.
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